CD7 and acute myeloid leukemia: The main move of this method is to place the generated CD7 CAR-T cells in a natural state without restricting fratricide to acquire the final surviving cells (48) Screened out by this targeted natural selection, these CD7 CAR T-cells demonstrated high therapeutic efficacy in both T-lymphocyte malignancies and AML, contributed by the high level of CAR and CD7 negative expression in vitro.